Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) has appointed Konstantin Konstantinov, Ph.D., to its Board of Directors. With nearly 30 years in the life sciences and bioprocessing industries, Dr. Konstantinov currently serves as Chief Technology Officer at Codiak BioSciences. His experience includes leadership roles at Genzyme and Bayer Healthcare, focusing on the development of biologic drugs and continuous biomanufacturing. The Board expresses optimism about his technical leadership and expertise in bioprocessing, which aligns with Repligen's mission to innovate in the bioprocessing sector.

Repligen Corporation (NASDAQ:RGEN) announced its participation in three upcoming investor conferences. These include the Craig-Hallum 19^th Annual Institutional Investor Conference on June 1, the William Blair 42^nd Annual Growth Stock Conference in Chicago from June 6-9, where CEO Tony J. Hunt will present on June 7, and the Jefferies Global Healthcare Conference in New York from June 8-10, with CFO Jon K. Snodgres presenting on June 9. Live webcasts of these presentations will be available on Repligen's Investor Relations website.

Repligen Corporation (NASDAQ:RGEN) reported first-quarter 2022 revenue of $206.4 million, reflecting a 45% year-over-year growth. Organic revenue surged by 44%, with base business growth at 37%.

COVID-related sales constituted 26% of total revenue. The company anticipates a decline in COVID-related demand but expects strong growth from its base products. Adjusted EPS rose to $0.92 from $0.68 year-over-year. For the full year, RGEN revises its revenue guidance down to $770-$800 million, adjusting expectations for COVID-related revenue.

Repligen Corporation (NASDAQ:RGEN) will announce its first quarter 2022 financial results on April 27, 2022, before the market opens. The company will host a conference call at 8:30 a.m. EDT on the same day to discuss these results and provide business updates. Interested participants can join the call toll-free at (844) 274-3999 for domestic listeners and (412) 317-5607 for international callers. A webcast will be available via the company's Investor Relations website, where the event will also be archived for later access.

Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 22-23, 2022. CEO Tony J. Hunt will engage in a fireside chat on March 22 at 9:45 a.m. EDT. A live webcast of the event will be available on the company’s Investor Relations website and can be replayed for a limited time afterward. Repligen is a leader in bioprocessing technology, supporting biopharmaceutical developers worldwide.

908 Devices (Nasdaq: MASS) has appointed Tony J. Hunt, President and CEO of Repligen Corporation (Nasdaq: RGEN), to its Board of Directors. Mr. Hunt brings over 20 years of experience in life sciences and bioprocessing. His previous roles include Chief Operating Officer at Repligen and President of Bioproduction at Life Technologies. The appointment aims to enhance 908 Devices' strategic insights and support its goal of developing a comprehensive bioanalytics platform. The company specializes in handheld mass spectrometry devices for critical applications in various markets.

Repligen Corporation (NASDAQ:RGEN) announced record revenue of $186.5 million for Q4 2021, marking a 72% increase year-over-year. For the full year, revenue reached $670.5 million, growing 83%. The company reported organic growth of 69% in Q4 and 71% for the year. Key metrics included a GAAP operating margin of 20.1% and an adjusted EPS of $0.81. Looking forward, RGEN anticipates revenue between $800-$830 million for 2022, predicting growth of 19%-24%.

Repligen Corporation (NASDAQ:RGEN) has launched three advanced affinity chromatography resins under the AVIPure® brand, designed specifically for gene therapy manufacturing. The resins—AVIPure® - AAV9, AVIPure® - AAV8, and AVIPure® - AAV2—were developed by Avitide LLC, addressing the demand for high-performance and caustic-stable solutions in the industry. This launch aims to enhance the efficiency and economics of gene therapy workflows. The company anticipates benefiting from strong customer adoption and expanded product lines in the future.

Repligen Corporation (NASDAQ:RGEN) will present virtually at the 11th Annual SVB Leerink Healthcare Conference from Feb. 14-18, 2022. Tony J. Hunt, President and CEO, is scheduled for a fireside chat on Feb. 18 at 3:00 p.m. EST. A live webcast will be available on Repligen's Investor Relations page and will be accessible for replay shortly after the event.

The company is a leader in bioprocessing technology, enhancing efficiencies for biopharmaceutical manufacturers.